Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Crit Care Med. May 4, 2015; 4(2): 139-151
Published online May 4, 2015. doi: 10.5492/wjccm.v4.i2.139
Published online May 4, 2015. doi: 10.5492/wjccm.v4.i2.139
Designing drug regimens for special intensive care unit populations
Brian L Erstad, Department of Pharmacy Practice and Science, University of Arizona College of Pharmacy, Tucson, AZ 85721-0207, United States
Author contributions: Erstad BL solely contributed to this work.
Conflict-of-interest: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Brian L Erstad, PhD, MCCM, Department of Pharmacy Practice and Science, University of Arizona College of Pharmacy, 1295 N. Martin Ave., Tucson, AZ 85721-0207, United States. blerstad@hotmail.com
Telephone: +1-520-6264289 Fax: +1-520-6267355
Received: August 5, 2014
Peer-review started: August 6, 2014
First decision: August 28, 2014
Revised: September 6, 2014
Accepted: February 4, 2015
Article in press: February 9, 2015
Published online: May 4, 2015
Processing time: 261 Days and 7.9 Hours
Peer-review started: August 6, 2014
First decision: August 28, 2014
Revised: September 6, 2014
Accepted: February 4, 2015
Article in press: February 9, 2015
Published online: May 4, 2015
Processing time: 261 Days and 7.9 Hours
Core Tip
Core tip: Special populations of intensive care units patients with more severe alterations in body size, shape, and composition pose unique challenges to clinicians faced with drug choice or dosing decisions. Appropriate drug choice or dosing in these populations must take into account a variety of factors from altered pharmacokinetic parameters to concomitant therapeutic interventions and co-morbidities.